164 related articles for article (PubMed ID: 35482986)
1. Intensity-modulated radiotherapy with more than 60 Gy improved the survival of inoperable patients with locally advanced esophageal squamous cell carcinoma: A population-based real-world study.
Zhang W; Xie Q; Zhu B; Wang X; He L; Zhang Y
Medicine (Baltimore); 2022 Apr; 101(16):e29166. PubMed ID: 35482986
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.
Wang L; Liu L; Cao Y; Chen X; Liu S; Li X; Han J; Wang Q; Han C
BMC Cancer; 2024 Jun; 24(1):679. PubMed ID: 38831450
[TBL] [Abstract][Full Text] [Related]
3. Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score-matched analysis.
Li C; Tan L; Liu X; Wang X; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Wang X; Bi N; Deng L; Wang W; Zhang T; Ni W; Chang X; Han W; Gao L; Wang S; Xiao Z
Thorac Cancer; 2021 Jun; 12(12):1831-1840. PubMed ID: 33949784
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic analysis of definitive radiotherapy for early esophageal carcinoma(T1-2N0M0): a multi-center retrospective study of Jing-Jin-ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group].
Lu N; Wang X; Li C; Wang L; Chen JQ; Zhang WC; Wang XM; Ge XL; Shen WB; Hu MM; Yuan QQ; Xu YG; Hao CL; Zhou ZG; Qie S; Xiao ZF; Zhu SC; Han C; Qiao XY; Pang QS; Wang P; Zhao YD; Sun XC; Zhang KX; Li L; Li GF; Liu ML; Wang YD
Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):139-144. PubMed ID: 32135649
[No Abstract] [Full Text] [Related]
5. Re-irradiation for local primary-recurrence esophageal squamous cell carcinoma treated with IMRT/VMAT.
Xiang G; Xu C; Chai G; Lyu B; Li Z; Wang B; Shi M; Zhao L
Radiat Oncol; 2023 Jul; 18(1):114. PubMed ID: 37430276
[TBL] [Abstract][Full Text] [Related]
6. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy Combined With Concurrent Nedaplatin-Based Chemotherapy for Stage II-III Esophageal Squamous Cell Carcinoma.
Zhu H; Lu X; Jiang J; Lu J; Sun X; Zuo Y
Dose Response; 2022; 20(1):15593258221076720. PubMed ID: 35273471
[TBL] [Abstract][Full Text] [Related]
8. Sequential boost of intensity-modulated radiotherapy with chemotherapy for inoperable esophageal squamous cell carcinoma: A prospective phase II study.
Fan XW; Wang HB; Mao JF; Li L; Wu KL
Cancer Med; 2020 Apr; 9(8):2812-2819. PubMed ID: 32100452
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Intensity-Modulated Proton Therapy Versus Intensity-Modulated Radiotherapy for Patients With Inoperable Esophageal Squamous Cell Carcinoma Undergoing Curative-Intent Concurrent Chemoradiotherapy.
Chang CL; Lin KC; Chen WM; Shia BC; Wu SY
J Thorac Oncol; 2024 May; 19(5):818-828. PubMed ID: 38154513
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed and cisplatin for locally advanced oesophageal squamous cell carcinoma.
Fu C; Li B; Guo L; Li H; Huang W; Gong H; Sun M; Wang Z; Zhou T; Liu C
Br J Radiol; 2014 May; 87(1037):20130656. PubMed ID: 24666012
[TBL] [Abstract][Full Text] [Related]
11. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and standard-dose intensity-modulated radiotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study.
Lan W; Lihong L; Chun H; Shutang L; Qi W; Liang X; Xiaoning L; Likun L
Strahlenther Onkol; 2022 Sep; 198(9):802-811. PubMed ID: 35029718
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
13. Intensity-Modulated Radiotherapy versus Three-Dimensional Conformal Radiotherapy in Definitive Chemoradiotherapy for Cervical Esophageal Squamous Cell Carcinoma: Comparison of Survival Outcomes and Toxicities.
Chen NB; Qiu B; Zhang J; Qiang MY; Zhu YJ; Wang B; Guo JY; Cai LZ; Huang SM; Liu MZ; Li Q; Hu YH; Li QW; Liu H
Cancer Res Treat; 2020 Jan; 52(1):31-40. PubMed ID: 31048664
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma.
Chen J; Su T; Lin Y; Wang B; Li J; Pan J; Chen C
Clin Transl Oncol; 2018 Mar; 20(3):411-419. PubMed ID: 28779422
[TBL] [Abstract][Full Text] [Related]
15. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.
Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
Radiat Oncol; 2017 Aug; 12(1):131. PubMed ID: 28810885
[TBL] [Abstract][Full Text] [Related]
16. Outcome of chemoradiotherapy using intensity-modulated radiation therapy for cervical esophageal cancer: a single institute experience.
Inada M; Nishimura Y; Ishikawa K; Uehara T; Wada Y; Oguma Y; Doi H; Nakamatsu K
Esophagus; 2021 Jul; 18(3):638-644. PubMed ID: 33417068
[TBL] [Abstract][Full Text] [Related]
17. Do higher radiation doses improve survival for cervical esophageal squamous cell cancer patients treated with definitive chemoradiotherapy using intensity-modulated radiotherapy? A propensity-score matched analysis.
Xie F; Liu T; Wang X; Dong J; Huang W; Sun H
J Cancer Res Ther; 2023 Dec; 19(6):1582-1588. PubMed ID: 38156925
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial.
Li H; Fang Y; Gu D; Du M; Zhang Z; Sun L; Zhou G; Ye J
Radiat Oncol; 2022 Jun; 17(1):105. PubMed ID: 35681233
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study of postoperative radiotherapy for locally advanced esophageal squamous cell carcinoma.
Zhang Z; Xu L; Di X; Zhang C; Ge X; Sun X
Ann Palliat Med; 2019 Nov; 8(5):708-716. PubMed ID: 31865731
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of S-1-Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang X; Han W; Zhang W; Wang X; Ge X; Lin Y; Zhou H; Hu M; Wang W; Liu K; Lu J; Qie S; Zhang J; Deng W; Wang L; Han C; Li M; Zhang K; Li L; Wang Q; Shi H; Yu Z; Zhao Y; Sun X; Shi Y; Pang Q; Zhou Z; Liang J; Chen D; Feng Q; Bi N; Zhang T; Deng L; Wang W; Liu W; Wang J; Zhai Y; Wang J; Chen W; Chen J; Xiao Z;
JAMA Netw Open; 2023 May; 6(5):e2312625. PubMed ID: 37195667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
